How should I manage a bipolar patient with treatment‑resistant depression who is currently on Austedo (dextromethorphan/quinidine) and lamotrigine 125 mg twice daily but remains depressed?

Management of Treatment-Resistant Bipolar Depression on Austedo and Lamotrigine

Optimize lamotrigine to 200 mg twice daily (400 mg/day total) as the first-line intervention, while closely monitoring for worsening depression or suicidality given the FDA black box warning on Austedo for depression in patients with movement disorders 1.

Critical Safety Consideration with Austedo

Your patient is on Austedo (deutetrabenazine) for tardive dyskinesia, which carries a black box warning specifically contraindicating use in patients with untreated or poorly controlled depression. The FDA label explicitly states: "Do not start taking AUSTEDO if you have Huntington's disease and are depressed (have untreated depression or depression that is not well controlled by medicine)" 1. While this warning is written for Huntington's disease, the mechanism applies to all patients—Austedo can cause or worsen depression, suicidal thoughts, and suicidal actions. You must reassess whether continuing Austedo is appropriate given the persistent depression, or at minimum ensure extremely close monitoring for mood deterioration.

Lamotrigine Optimization

The current dose of lamotrigine 125 mg BID (250 mg/day total) is suboptimal:

• Standard effective dose for bipolar depression prevention is 200 mg/day, with maximum doses up to 400 mg/day 2, 3
• Recent network meta-analysis demonstrates lamotrigine 200 mg/day significantly outperforms placebo for depressive symptoms (effect size -1.53,95% CI -2.13 to -0.93) 3
• Increase to 200 mg BID (400 mg/day total) unless contraindicated, using gradual titration to minimize rash risk 2

Augmentation Strategies if Lamotrigine Optimization Fails

After optimizing lamotrigine, if depression persists after 4-6 weeks, consider these evidence-based augmentation options in order of strength:

First-Line Augmentation Options:

1. Quetiapine extended-release 150-300 mg/day

   • Network meta-analysis shows both 150 mg and 300 mg doses significantly reduce depressive symptoms compared to placebo 3
   • Well-established efficacy in bipolar depression 4, 5

2. Lumateperone 42 mg/day

   • Newer atypical antipsychotic with demonstrated efficacy (effect size -0.36) 3
   • May have better tolerability profile than older antipsychotics

3. Bright light therapy (BLT)

   • Administer 30 minutes daily, preferably morning or mid-day 6
   • Clinical improvement typically within 1-2 weeks, response/remission by 4-6 weeks 6
   • Critical caveat: Requires antimanic prophylaxis and close monitoring for mood switches, especially in Bipolar I 6
   • Can be combined with pharmacotherapy for enhanced efficacy 6

Alternative Augmentation (if above fail):

1. Lithium augmentation

   • Recommended as first-line augmentation strategy after failed antidepressant trial 5
   • Requires monitoring of levels, renal function, and thyroid

2. Ketamine or esketamine

   • Rapid-acting glutamatergic modulation with fastest antidepressant effect 4
   • Low risk of phase change compared to traditional antidepressants 4
   • Requires specialized administration

What NOT to Do

• Avoid antidepressant monotherapy in bipolar depression—always combine with mood stabilizer or atypical antipsychotic 5
• Do not add traditional antidepressants (SSRIs, SNRIs) without adequate mood stabilization, as this increases risk of mood switching 5
• Do not continue current regimen unchanged—the combination of Austedo's depressogenic effects and suboptimal lamotrigine dosing is insufficient

Monitoring Protocol

Given Austedo's depression risk:

• Weekly mood assessments for first month after any medication change
• Specific screening for: crying spells, loss of interest, sleep changes, guilt, hopelessness, irritability, suicidal ideation 1
• If depression worsens or suicidal ideation emerges, discontinue Austedo immediately and reassess risk-benefit of TD treatment versus mood stability

Clinical Algorithm

1. Immediate: Assess suicide risk and severity of depression worsening on Austedo
2. Week 1: Increase lamotrigine toward 400 mg/day (if not contraindicated by drug interactions)
3. Week 6-8: If inadequate response, add quetiapine XR 150-300 mg/day OR lumateperone 42 mg/day
4. Week 2 onward: Consider adding bright light therapy 30 min/day (with antimanic monitoring)
5. Throughout: Monitor closely for Austedo-induced mood deterioration; discontinue if depression worsens

The evidence strongly supports that your patient's current regimen is inadequate both in lamotrigine dosing and in addressing the potential depressogenic effects of Austedo 1, 2, 3.